Effects of resistance-associated NS5A mutations in hepatitis C virus on viral production and susceptibility to antiviral reagents

Sayuri Nitta, Yasuhiro Asahina, Mami Matsuda, Norie Yamada, Ryuichi Sugiyama, Takahiro Masaki, Ryosuke Suzuki, Nobuyuki Kato, Mamoru Watanabe, Takaji Wakita, Takanobu Kato

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Direct-acting antivirals (DAAs) for hepatitis C virus (HCV) have potent anti-HCV effects but may provoke resistance-associated variants (RAVs). In this study, we assessed the characteristics of these RAVs and explored efficacious anti-HCV reagents using recombinant HCV with NS5A from a genotype 1b strain. We replaced the NS5A of JFH1 with that of Con1 (JFH1/5ACon1) and introduced known NS5A inhibitor resistance mutations (L31M, L31V, L31I and Y93H) individually or in combination. Susceptibilities against anti-HCV reagents were also investigated. RAVs with Y93H exhibited high extracellular core antigen levels and infectivity titers. Variants with any single mutation showed mild to moderate resistance against NS5A inhibitors, whereas variants with double mutations at both L31 and Y93 showed severe resistance. The variants with mutations exhibited similar levels of susceptibility to interferon (IFN)-α, IFN-λ 1, IFN-λ 3 and Ribavirin. Variants with the Y93H mutation were more sensitive to protease inhibitors compared with JFH1/5ACon1. In conclusion, the in vitro analysis indicated that the Y93H mutation enhanced infectious virus production, suggesting advantages in the propagation of RAVs with this mutation. However, these RAVs were susceptible to protease inhibitors. Thus, a therapeutic regimen that includes these reagents is a promising means to eradicate these RAVs.

Original languageEnglish
Article number34652
JournalScientific Reports
Volume6
DOIs
Publication statusPublished - Oct 5 2016

Fingerprint

Hepacivirus
Antiviral Agents
Mutation
Interferons
Protease Inhibitors
Galectin 3
Ribavirin
Genotype
Viruses
Antigens

ASJC Scopus subject areas

  • General

Cite this

Effects of resistance-associated NS5A mutations in hepatitis C virus on viral production and susceptibility to antiviral reagents. / Nitta, Sayuri; Asahina, Yasuhiro; Matsuda, Mami; Yamada, Norie; Sugiyama, Ryuichi; Masaki, Takahiro; Suzuki, Ryosuke; Kato, Nobuyuki; Watanabe, Mamoru; Wakita, Takaji; Kato, Takanobu.

In: Scientific Reports, Vol. 6, 34652, 05.10.2016.

Research output: Contribution to journalArticle

Nitta, S, Asahina, Y, Matsuda, M, Yamada, N, Sugiyama, R, Masaki, T, Suzuki, R, Kato, N, Watanabe, M, Wakita, T & Kato, T 2016, 'Effects of resistance-associated NS5A mutations in hepatitis C virus on viral production and susceptibility to antiviral reagents', Scientific Reports, vol. 6, 34652. https://doi.org/10.1038/srep34652
Nitta, Sayuri ; Asahina, Yasuhiro ; Matsuda, Mami ; Yamada, Norie ; Sugiyama, Ryuichi ; Masaki, Takahiro ; Suzuki, Ryosuke ; Kato, Nobuyuki ; Watanabe, Mamoru ; Wakita, Takaji ; Kato, Takanobu. / Effects of resistance-associated NS5A mutations in hepatitis C virus on viral production and susceptibility to antiviral reagents. In: Scientific Reports. 2016 ; Vol. 6.
@article{49cdf7d0b6fa4f17b837f5d98d703fdc,
title = "Effects of resistance-associated NS5A mutations in hepatitis C virus on viral production and susceptibility to antiviral reagents",
abstract = "Direct-acting antivirals (DAAs) for hepatitis C virus (HCV) have potent anti-HCV effects but may provoke resistance-associated variants (RAVs). In this study, we assessed the characteristics of these RAVs and explored efficacious anti-HCV reagents using recombinant HCV with NS5A from a genotype 1b strain. We replaced the NS5A of JFH1 with that of Con1 (JFH1/5ACon1) and introduced known NS5A inhibitor resistance mutations (L31M, L31V, L31I and Y93H) individually or in combination. Susceptibilities against anti-HCV reagents were also investigated. RAVs with Y93H exhibited high extracellular core antigen levels and infectivity titers. Variants with any single mutation showed mild to moderate resistance against NS5A inhibitors, whereas variants with double mutations at both L31 and Y93 showed severe resistance. The variants with mutations exhibited similar levels of susceptibility to interferon (IFN)-α, IFN-λ 1, IFN-λ 3 and Ribavirin. Variants with the Y93H mutation were more sensitive to protease inhibitors compared with JFH1/5ACon1. In conclusion, the in vitro analysis indicated that the Y93H mutation enhanced infectious virus production, suggesting advantages in the propagation of RAVs with this mutation. However, these RAVs were susceptible to protease inhibitors. Thus, a therapeutic regimen that includes these reagents is a promising means to eradicate these RAVs.",
author = "Sayuri Nitta and Yasuhiro Asahina and Mami Matsuda and Norie Yamada and Ryuichi Sugiyama and Takahiro Masaki and Ryosuke Suzuki and Nobuyuki Kato and Mamoru Watanabe and Takaji Wakita and Takanobu Kato",
year = "2016",
month = "10",
day = "5",
doi = "10.1038/srep34652",
language = "English",
volume = "6",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Effects of resistance-associated NS5A mutations in hepatitis C virus on viral production and susceptibility to antiviral reagents

AU - Nitta, Sayuri

AU - Asahina, Yasuhiro

AU - Matsuda, Mami

AU - Yamada, Norie

AU - Sugiyama, Ryuichi

AU - Masaki, Takahiro

AU - Suzuki, Ryosuke

AU - Kato, Nobuyuki

AU - Watanabe, Mamoru

AU - Wakita, Takaji

AU - Kato, Takanobu

PY - 2016/10/5

Y1 - 2016/10/5

N2 - Direct-acting antivirals (DAAs) for hepatitis C virus (HCV) have potent anti-HCV effects but may provoke resistance-associated variants (RAVs). In this study, we assessed the characteristics of these RAVs and explored efficacious anti-HCV reagents using recombinant HCV with NS5A from a genotype 1b strain. We replaced the NS5A of JFH1 with that of Con1 (JFH1/5ACon1) and introduced known NS5A inhibitor resistance mutations (L31M, L31V, L31I and Y93H) individually or in combination. Susceptibilities against anti-HCV reagents were also investigated. RAVs with Y93H exhibited high extracellular core antigen levels and infectivity titers. Variants with any single mutation showed mild to moderate resistance against NS5A inhibitors, whereas variants with double mutations at both L31 and Y93 showed severe resistance. The variants with mutations exhibited similar levels of susceptibility to interferon (IFN)-α, IFN-λ 1, IFN-λ 3 and Ribavirin. Variants with the Y93H mutation were more sensitive to protease inhibitors compared with JFH1/5ACon1. In conclusion, the in vitro analysis indicated that the Y93H mutation enhanced infectious virus production, suggesting advantages in the propagation of RAVs with this mutation. However, these RAVs were susceptible to protease inhibitors. Thus, a therapeutic regimen that includes these reagents is a promising means to eradicate these RAVs.

AB - Direct-acting antivirals (DAAs) for hepatitis C virus (HCV) have potent anti-HCV effects but may provoke resistance-associated variants (RAVs). In this study, we assessed the characteristics of these RAVs and explored efficacious anti-HCV reagents using recombinant HCV with NS5A from a genotype 1b strain. We replaced the NS5A of JFH1 with that of Con1 (JFH1/5ACon1) and introduced known NS5A inhibitor resistance mutations (L31M, L31V, L31I and Y93H) individually or in combination. Susceptibilities against anti-HCV reagents were also investigated. RAVs with Y93H exhibited high extracellular core antigen levels and infectivity titers. Variants with any single mutation showed mild to moderate resistance against NS5A inhibitors, whereas variants with double mutations at both L31 and Y93 showed severe resistance. The variants with mutations exhibited similar levels of susceptibility to interferon (IFN)-α, IFN-λ 1, IFN-λ 3 and Ribavirin. Variants with the Y93H mutation were more sensitive to protease inhibitors compared with JFH1/5ACon1. In conclusion, the in vitro analysis indicated that the Y93H mutation enhanced infectious virus production, suggesting advantages in the propagation of RAVs with this mutation. However, these RAVs were susceptible to protease inhibitors. Thus, a therapeutic regimen that includes these reagents is a promising means to eradicate these RAVs.

UR - http://www.scopus.com/inward/record.url?scp=84989865060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989865060&partnerID=8YFLogxK

U2 - 10.1038/srep34652

DO - 10.1038/srep34652

M3 - Article

VL - 6

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 34652

ER -